The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 15, 2006, Pages 2107-2117

  Colice, Gene L ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Asthma; Ciclesonide; Inhaled corticosteroid

Indexed keywords

CICLESONIDE; CORTICOSTEROID; HYDROCORTISONE; PREGNANE DERIVATIVE;

ADULT; ANIMAL; ASTHMA; BLOOD; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EXPERT WITNESS; HUMAN; INHALATION TEST; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; URINE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANIMALS; ASTHMA; BRONCHIAL PROVOCATION TESTS; CHILD; EXPERT TESTIMONY; HUMANS; HYDROCORTISONE; PREGNENEDIONES; RANDOMIZED CONTROLLED TRIALS;

EID: 33750098929     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.15.2107     Document Type: Review

References (55)

1. EXPERT PANEL II: Guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program. February 1997.
2. British guideline on the management of asthma. Thorax (2003) 52:i1-i94.
3. BOULET LP, BECKER A, BERUBE D et al.: Canadian asthma consensus report, 1999. CMAJ (1999) 161:S1-S61.
4. GLOBAL INITIATIVE FOR ASTHMA: Global strategy for asthma management and prevention. NHLBI (2002).
5. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma. J. Allergy Clin. Immunol. (1992) 90:32-42.
6. TRIGG CJ, MANOLITSAS ND, WANG J et al.: Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am. J. Respir. Crit. Care Med. (1994) 150:17-22.
7. DJUKANOVIC R, WILSON JW, BRITTEN KM et al.: Effects of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis. (1992) 148:669-674.
8. BATEMAN ED, BOUSHEY HA, BOUSQUET J et al.: Can guideline-defined asthma control be achieved? Am. J. Respir. Crit. Care Med. (2004) 170:836-844.
9. SIN DD, MAN SFP: Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch. Intern. Med. (2002) 162:1591-1595.
10. DONAHUE JG, WEISS ST, LIVINGSTON JM et al.: Inhaled steroids and the risk of hospitalization for asthma. JAMA (1997) 277:887-891. (Pubitemid 27123948)
11. SUISSA S, ERNST P: Inhaled corticosteroids: impact on asthma morbidity and mortality. J. Allergy Clin. Immunol. (2001) 107:937-944.
12. SUISSA S, ERNST P, BENAYOUN S et al.: Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. (2000) 343:332-336.
13. GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Institutes of Health. March (2001):2701A.
14. PELAIA G, VATRELLA A, CUDA G et al.: Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci. (2003) 72:1549-1561. (Pubitemid 36120783)
15. COLICE GL: Comparing inhaled corticosteroids. Respir. Care (2000) 45:846-853.
16. BUSSE WW, BRAZINSKY S, JACOBSON K et al.: Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol. (1999) 104:1215-1222.
17. Physicians Desk Reference (58th edn). Thomson PD (Ed.), Thompson Publishing Montvale, NJ, USA (2006):1504-1507.
18. REYNOLDS NA, SCOTT LJ: Ciclesonide. Drugs (2004) 64:511-519.
19. BERGER WE: Ciclesonide, a novel inhaled corticosteroid for the treatment of persistent asthma. Therapy (2005) 2:167-178.
20. STOECK M, RIEDEL R, HOCHHAUS G et al.: In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J. Pharm. Experimental Ther. (2004) 309:249-258.
21. NEWMAN S, SALMON A, NAVE R, DROLLMAN A: High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir. Med. (2006) 100:375-384.
22. LEUNG SY, EYNOTT P, NATH P, CHUNG KF: Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features. J. Allergy Clin. Immunol. (2005) 115:989-996.
23. BELVISI MG, BUNDSCHUH DS, STOECK M et al.: Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J. Pharm. Experimental Ther. (2005) 314:568-574.
24. NAVE R, MEYER W, FUHST R et al.: Formation of fatty acid conjugates of clclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pul. Pharmacol. Ther. (2005) 18:390-396.
25. NAVE R, BETHKE TD, VAN MARLE SP, ZECH K: Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. (2004) 43:479-486.
26. PEET CF, ENOS T, NAVE AR et al.: Identification of enzymes involved in Phase I metabolism of ciclesonide by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. (2005) 30:275-286.
27. NAVE R, DROLLMANN A, STEINIJANS VW et al.: Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin. Int. J. Clin. Pharmacol. Ther. (2005) 43:264-270.
28. NAVE R, ZECH K, BETHKE TD: Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur. J. Clin. Pharm. (2005) 61:203-208.
29. RICHTER K, KANNIESS F, BIBERGER C et al.: Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J. Clin. Pharm. (2005) 45:146-152.
30. ROHATGI S, LUO Y, SHEN L et al.: Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am. J. Therapeutics (2005) 12:201-209. • This paper provides useful insights into the influence of protein binding on the systemic activity on a corticosteroid. (Pubitemid 40825123)
31. ROHATGI S, ARYA V, ZECH K et al.: Population pharmacokinetics and pharmacodynamics of ciclesonide. J. Clin. Pharmacol. (2003) 43:365-378.
32. LARSEN BB, NIELSEN LP, ENGLESTATTER R et al.: Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy (2003) 58:207-212. (Pubitemid 36609358)
33. GAUVREAU GM, BOULET LP, POSTMA DS et al.: Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J. Allergy Clin. Immunol. (2005) 116:285-291.
34. TAYLOR DA, JENSEN MW, KANABAR V et al.: A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am. J. Respir. Crit. Care Med. (1999) 160:237-243.
35. KANNIESS F, RICHTER K, BOHME S et al.: Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pul. Pharmacol. Ther. (2001) 14:141-147.
36. DEROM E, VAN DE VELDE V, MARISSENS S et al.: Effects of inhaled ciclesonide and fluticasone pripionate on cortisol secretion and airway responsiveness to adenosine 5′ monophosphate in asthmatic patients. Pul. Pharmcol. Ther. (2005) 18:328-336.
37. LEE DK, FARDON TC, BATES CE et al.: Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest (2005) 127:851-860. (Pubitemid 40775515)
38. LEE DK, HAGGART K, CURRIE GP et al.: Effects of hydrofluoroalkane formulations of ciclesonide 400 μg once daily vs fluticasone 250 μg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br. J. Clin. Pharmacol. (2004) 58:26-33.
39. ZIETKOWSKI Z, BODZENTA-LUKASZYK A, TOMASIAK MM et al.: Effect of ciclesonide and fluticasone on exhaled nitric oxide in patients with mild allergic asthma. Respir. Med. (2006) 100(9):1651-1656.
40. WEINBRENNER A, HUNEKE D, ZSCHIESCHE M et al.: Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J. Clin. Endo. Metab. (2002) 87:2160-2163.
41. SZEFLER S, ROHATGI S, WILLIAMS J et al.: Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest (2005) 128:1104-1114. •• The authors of this paper perform a rigorous assessment of the systemic effects of ciclesonide after dosing for 1 month. (Pubitemid 41324383)
42. LIPWORTH BJ, KALINER MA, LAFORCE CF et al.: Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann. Allergy Asthma Immunol. (2005) 94:465-472.
43. AGERTOFT L, PEDERSEN S: Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J. Allergy Clin. Immunol. (2005) 115:940-945.
44. AGERTOFT L, PEDERSEN S: Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J. Allergy Clin. Immunol. (1999) 104:948-952.
45. AGERTOFT L, PEDERSEN S: Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose-response study. Eur. Respir. J. (1997) 10:1507-1512.
46. CHAPMAN KR, PATEL P, D'URZO AD et al.: Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy (2005) 60:330-337. (Pubitemid 40293349)
47. LANGDON CG, ADLER M, MEHRA S et al.: Once-daily ciclesonide 80 or 320 μg for 12 weeks is safe and effective in patients with persistent asthma. Respir. Med. (2005) 99:1275-1285.
48. PEARLMAN DS, BERGER WE, KERWIN E et al.: Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J. Allergy Clin. Immunol. (2005) 116:1206-1212.
49. POSTMA DS, SEVETTE C, MARTINAT Y et al.: Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning of evening. Eur. Respir. J. (2001) 17:1083-1088.
50. BOULET LP, DROLLMANN A, MAGYAR P et al.: Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir. Med. (2006) 100:785-794.
51. BATEMAN E, KARPEL J, CASALE T et al.: Ciclesonide reduces oral corticosteroid use in adults with severe, persistent asthma while maintaining asthma control. Chest (2006) 129:1176-1187. •• This article provides important information about the efficacy of ciclesonide in patients with very severe asthma.
52. BUHL R, VINKLER I, MAGYAR P et al.: Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pul. Pharm. Ther. (2006) 19(6):404-412.
53. HANSEL TT, BENEZET O, KAFE H et al.: A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin. Ther. (2006) 28:906-920.
54. NIPHADKAR P, JAGANNATH K, JOSHI J et al.: Comparison of the efficacy of ciclesonide 160 μg QD and budesonide 200 μg BID in adults with persistent asthma. Clin. Ther. (2005) 27:1752-1763.
55. SKONER D, BAENA-CAGNANI CE, MASPERO J et al.: Once-daily ciclesonide has no effect on growth velocity, as assessed by stadiometer height, in children with mild, persistent asthma. Proc. Amer. Thorac. Soc. (2006) 3:A3024.